Drug Patents owned by Sucampo Pharma Llc

1. List of Amitiza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7064148 SUCAMPO PHARMA LLC Chloride channel opener
Aug, 2022

(5 months ago)

US8097653 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation
Nov, 2022

(2 months ago)

US8389542 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation
Nov, 2022

(2 months ago)

US6982283 SUCAMPO PHARMA LLC Method for treating drug-induced constipation
Dec, 2022

(a month ago)

US7795312 SUCAMPO PHARMA LLC Method for treating abdominal discomfort
Sep, 2024

(1 year, 7 months from now)

US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder
Sep, 2025

(2 years from now)

US8779187 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(3 years from now)

US8338639 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(3 years from now)

US8026393 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Oct, 2027

(4 years from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for treating constipation in a patient with opioid-induced constipation by opening cic channels; Method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic); Method for treating constipation by opening cic channels in a mammalian subject; Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation; Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome; Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; Method for the long term treatment of chronic constipation in a human subject

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in